Two prostate cancer treatments in phase III prolong patient survival May 14, 2020 By Lee Landenberger No Comments New data show Johnson & Johnson’s Erleada (apalutamide) and Xtandi (enzalutamide) from Pfizer Inc. and Astellas Pharma Inc. both prolonged overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC).Read More